Fortress Biotech Stock News

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow

Fortress Biotech, Inc. (NASDAQ:FBIO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Co-Founder President and Chief Executive

Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 20% and 23.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the

Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid

Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on effic

SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and c

Company also strengthens Board of Directors with addition of Stanford Professor Vibeke Strand, M.D., MACR, FACP Company also strengthens Board of Directors with addition of Stanford Professor Vibeke S

MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, develop

Topline data expected in the first half of 2023 Topline data expected in the first half of 2023

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million